ArticleTherapeutic advances in neurological disorders2026
Clinical heterogeneity and immunotherapy outcomes in anti-GAD65 antibody-associated autoimmune encephalitis: a retrospective study.
Article in Therapeutic advances in neurological disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-glutamic acid decarboxylase 65 (GAD65) antibody-associated autoimmune encephalitis (AE) is characterized by diverse neurological manifestations and systemic autoimmune comorbidities, posing diagnostic and therapeutic challenges. This study aimed to investigate the clinical heterogeneity, immunological characteristics, neuropathological features, and therapeutic outcomes in patients with anti-GAD65 AE. A retrospective study was performed in six patients with anti-GAD65 AE diagnosed at Guangdong Provincial People's Hospital. Collected data included demographic, clinical manifestations, cerebrospinal fluid (CSF) profiles, neuroimaging findings, antibody titers, immunotherapy regimens, and histopathology. Initial presentations included epilepsy (50%), hyperthyroidism (33%), and stiff-person syndrome (17%). Concurrent autoimmune diseases (type 1 diabetes, autoimmune thyroiditis, and polyendocrine syndrome) were present in half of the patients. All patients exhibited elevated anti-GAD65 antibody titers in serum and CSF. CSF analysis revealed lymphocytic pleocytosis in one patient and oligoclonal bands in four tested cases. Acute immunotherapy involving corticosteroids and intravenous immunoglobulin achieved seizure control in 83%. Maintenance therapy with mycophenolate mofetil or biologics (e.g., ofatumumab, telitacicept) elicited heterogeneous serological responses, including antibody titer rebound despite clinical stability. Notably, Case 6 represented the first reported case worldwide of AE with triple positivity (anti-GAD65, anti-GABA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.